Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Substanzprofil
Psilocybin ist ein natürlich vorkommendes Tryptamin-Derivat, das in über 200 Pilzarten der Gattung Psilocybe gefunden wird. Nach oraler Einnahme wird es durch alkalische Phosphatasen rasch zu Psilocin dephosphoryliert, welches als eigentlicher Wirkstoff die Blut-Hirn-Schranke überwindet. Psilocin wirkt primär als Agonist am serotonergen 5-HT2A-Rezeptor und löst tiefgreifende Veränderungen der Wahrnehmung, des Denkens und des emotionalen Erlebens aus. In klinischen Studien zeigt Psilocybin vielversprechende Ergebnisse bei der Behandlung von therapieresistenter Depression, Suchterkrankungen und existenzieller Angst bei terminalen Erkrankungen.
Primary mechanism of psychedelic action via cortical serotonin receptor activation
Decreases connectivity in the DMN, facilitating novel cognitive patterns
Promotes dendritic spine growth and synaptogenesis via BDNF/TrkB signaling
Berichtete subjektive Effekte basierend auf klinischen und Community-Daten
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
Subjective Experience Following Psilocybin
Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy.
Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development.
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons.
[Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches].
Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats.
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.
[Perspectives opened up by the physiopathological understanding of psychiatric disorders].
Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions.
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.
Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.
Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials.
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies.
Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression.
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
Psychedelic therapy and cultural humility.
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder.
Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial.
Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.
Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.
Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention.
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review.
The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review.
A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry.
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.
Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine.
Safety Profile of Psilocybin for Cocaine Use Disorder
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks.
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter
RCT of Psilocybin-assisted CBT for Depression
Psilocybin to Treat Depression in Spinal Cord Injury
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.
Emerging mechanisms of psilocybin-induced neuroplasticity.
Die wichtigsten Fragen zu Psilocybin